← REGENERON PHARMACEUTICALS, INC. REGN
Market Price
$803.52
Market Cap
$84.48B
P/E Ratio
19.37
Revenue (FY 2025)
↑1.0% YoY
$14.34B
3-Yr CAGR: 5.6%
Net Income
↑2.1% YoY
$4.50B
Net Margin: 31.4%
Free Cash Flow
↑11.3% YoY
$4.08B
FCF Yield: 4.83%
EPS (Diluted)
↑8.2% YoY
$41.48
Basic: $43.07
Return on Equity
Efficiency
14.4%
ROA: 948.8%
📊 Multi-Year Historical Performance & Trends
Financial Performance History
Revenue, Net Income & Free Cash Flow
Margins Trend (%)
Gross, Operating & Net Margins
Balance Sheet Strength
Cash, Debt & Equity
Cash Flow Generation
Operating Cash Flow vs CapEx vs FCF
📈 Year-over-Year (YoY) Growth History (REGN)
All monetary values in millions ($M)| Fiscal Year | Revenue | Revenue YoY | Gross Profit | Net Income | Net Inc YoY | Diluted EPS | EPS YoY | Op. Cash Flow | Free Cash Flow | FCF YoY |
|---|---|---|---|---|---|---|---|---|---|---|
| FY 2016 | $4,860.4M | — | $4,665.8M | $895.5M | — | $7.70 | — | $1,473.4M | $961.5M | — |
| FY 2017 | $5,872.2M | +20.8% | $5,669.7M | $1,198.5M | +33.8% | $10.34 | +34.3% | $1,307.1M | $1,034.5M | +7.6% |
| FY 2018 | $6,710.8M | +14.3% | $6,276.7M | $2,444.4M | +104.0% | $21.29 | +105.9% | $2,195.1M | $1,812.0M | +75.2% |
| FY 2019 | $7,863.4M | +17.2% | $7,081.2M | $2,115.8M | -13.4% | $18.46 | -13.3% | $2,430.0M | $2,000.4M | +10.4% |
| FY 2020 | $8,497.1M | +8.1% | $7,377.2M | $3,513.2M | +66.0% | $30.52 | +65.3% | $2,618.1M | $2,003.5M | +0.2% |
| FY 2021 | $16,071.7M | +89.1% | $10,771.7M | $8,075.3M | +129.9% | $71.97 | +135.8% | $7,081.3M | $6,529.4M | +225.9% |
| FY 2022 | $12,172.9M | -24.3% | $10,612.5M | $4,338.4M | -46.3% | $38.22 | -46.9% | $5,014.9M | $4,424.8M | -32.2% |
| FY 2023 | $13,117.2M | +7.8% | $11,301.4M | $3,953.6M | -8.9% | $34.77 | -9.0% | $4,594.0M | $3,875.4M | -12.4% |
| FY 2024 | $14,202.0M | +8.3% | $12,231.5M | $4,412.6M | +11.6% | $38.34 | +10.3% | $4,420.5M | $3,664.6M | -5.4% |
| FY 2025 | $14,342.9M | +1.0% | $6,277.9M | $4,504.9M | +2.1% | $41.48 | +8.2% | $4,978.9M | $4,080.5M | +11.3% |
Valuation
Market Price
$803.52
Market Cap
$84.48B
Enterprise Value
$83.34B
P/E Ratio
19.37
P/B Ratio
2.70
FCF Yield
4.83%
Dividend Yield
N/A
Shares Outstanding
Profitability & Margins
Gross Margin
43.77%
Operating Margin
24.95%
Net Margin
31.41%
Return on Equity (ROE)
14.41%
Return on Assets (ROA)
948.80%
Asset Turnover
30.21x
Revenue 3-Yr CAGR
5.62%
Financial Health & Liquidity
Current Ratio
0.11
Cash Ratio
0.71
Debt / Equity
0.064
Debt / Assets
4.183
Cash & Equivalents
$3.12B
Total Debt
$1.99B
Book Value / Share
$298.14
Cash Flow Efficiency
Operating Cash Flow
$4.98B
Capital Expenditures (CapEx)
$898.40M
Free Cash Flow
$4.08B
OCF / Revenue
34.71%
FCF / Revenue
28.45%
FCF 3-Yr CAGR
-2.66%
Per Share Metrics
EPS (Diluted)
$41.48
EPS (Basic)
$43.07
Dividends / Share
N/A
Book Value / Share
$298.14
EPS YoY Growth
8.19%
Balance Sheet (FY 2025)
Total Assets
$474.80M
Total Liabilities
$4.37B
Stockholders' Equity
$31.26B
Current Assets
$474.80M
Current Liabilities
$4.37B